Bullish & Foolish
Full ESLA fundamentals All 466 on the Survival Watch

ESLAESTRELLA IMMUNOPHARMA, INC.

Is Estrella Immunopharma struggling financially?

Yes, by its own account. Estrella Immunopharma told the SEC on 18 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$32.0M
Source filing
10-Q 18 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 0months

    If the burn speeds up

    Empty by Jun 2026

  • 1month

    If it eases off

    Empty by Jul 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$100K

÷

Cash burned over the last 12 months

$17.0M

What Estrella Immunopharma told the SEC

…of compliance submitted to Nasdaq on February 24, 2026, the Company intends to hold a joint 2025/2026 annual meeting of shareholders prior to such deadline. Going Concern In assessing the Company’s liquidity and the substantial doubt about its ability to continue as a going concern, the Company monitors and analyzes cash on hand and operating expenditure commitments. The Company’s liquidity needs are to meet…

ESTRELLA IMMUNOPHARMA, INC., Form 10-Q, filed 18 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 17.6% share-count increase The company issued stock. Each share now owns 15.0% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt